Stocks and Investing Stocks and Investing
Tue, September 13, 2022
Mon, September 12, 2022

Paul Matteis Maintained (BIIB) at Hold with Decreased Target to $223 on, Sep 12th, 2022


Published on 2024-10-27 22:59:10 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $230 to $223 on, Sep 12th, 2022.

Paul has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $200 on, Thursday, July 21st, 2022


These are the ratings of the 4 analyists that currently disagree with Paul


  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $250 on, Thursday, July 21st, 2022
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $230 on, Monday, July 18th, 2022
Contributing Sources